logo
logo

Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13

Nov 11, 2020•over 4 years ago

Amount Raised

$35 Million

Round Type

series a

San Diego

Description

Inipharm today announced the close of a $35 million Series A financing round. Founded in 2018, the company is focused on discovering and developing therapies for liver and related diseases, with its initial program focused on those associated with the genetically defined target HSD17B13. The Series A funding will support the advancement of Inipharm’s lead program through IND filing and into clinical trials. The company also announced that Brian Daniels, M.D., partner at 5AM Ventures, and Hannah Chang, M.D., Ph.D., managing director at Wu Capital, have joined Inipharm’s board of directors.

Company Information

Company

Inipharm

Location

San Diego, California, United States

About

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm’s lead programs are focused on the highly validated genetic target, HSD17B13. Extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech